Background: Routine surveillance for Fontan-associated liver disease (FALD), including hepatic imaging and laboratory studies, is standard care for adolescents and adults with Fontan circulation, yet the prognostic utility of these findings for predicting adverse outcomes remains unknown.Methods: We retrospectively reviewed 368 patients with Fontan circulation who underwent hepatic imaging between 2010 and 2023, linked to state death certificates. FALD severity was classified as severe (abnormal imaging with varices, ascites, or splenomegaly [VAS]), moderate (abnormal laboratory results with or without imaging abnormalities, or splenomegaly with otherwise normal imaging), or mild (normal laboratory results). Associations between surveillance findings and advanced heart failure therapy referral (AHFR) or all-cause mortality were assessed.Results: Median age at initial imaging encounter was 20.6 years; 54.6% were male, 54.1% had a systemic left ventricle, and 17.1% had heterotaxy. FALD was severe in 31.8%, moderate in 48.9%, and mild in 19.3%. AHFR and mortality increased with FALD severity: severe (17.9% AHFR, 20.5% mortality), moderate (12.2%, 10.6%), and mild (2.8%, 2.8%) (p<0.01 and p<0.001, respectively). Laboratory abnormalities were present in 76.1% of those with severe FALD and were independently associated with adverse outcomes. Ten-year overall survival was 96%, 86%, and 67%, and event-free survival was 93%, 74%, and 50%, for mild, moderate, and severe FALD, respectively.Conclusions: FALD severity, classified using routine clinical test results, effectively risk-stratifies Fontan patients for AHFR-free survival and all-cause mortality, providing a clinically accessible framework to guide management and inform timely referral for advanced therapies.